Key information

🔎 Fund Overview

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It is engaged in the clinical development of compounds that target pathways at the interface of immunity and metabolism. Its lead candidate is NX-13, an oral, gut-selective NLRX1 agonist. It is developing NX-13 as a once-daily oral treatment for ulcerative colitis (UC) that targets the NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines in UC. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. In addition to NX-13, it has discovered several preclinical product candidates, such as LABP-73, LABP-66 and LABP-69. LABP-73, an oral, small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.